Overexpression of activating transcription factor 5 in human rectal cancer

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 827-831

  Kong, Xiangheng ^a   Meng, Wenjian ^a   Zhou, Zongguang ^a   Li, Yuan ^a   Zhou, Bin ^a   Wang, Rong ^a   Zhan, Lan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Activating transcription factor 5; Clinicopathological feature; Human rectal cancer; Immunohistochemical staining; Quanti tative real time polymerase chain reaction

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 5; BIOLOGICAL MARKER; MESSENGER RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RECTUM CANCER;

EID: 79960210376     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.295     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu JQ and Ward E: Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Markowitz SD and Bertagnolli MM: Molecular origins of cancer: molecular basis of colorectal cancer. New Engl J Med 361: 2449-2460, 2009.
3. Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366-378, 2009.
4. Sung JJ, Lau JY, Goh KL, Leung WK; Asia Pacific Working Group on Colorectal Cancer: Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 6: 871-876, 2005.
5. Hansen MB, Mitchelmore C, Kjaerulff KM, Rasmussen TE, Pedersen KM and Jensen NA: Mouse Atf5: molecular cloning of two novel mRNAs, genomic organization, and odorant sensory neuron localization. Genomics 80: 344-350, 2002.
6. Pati D, Meistrich ML and Plon SE: Human Cdc34 and Rad6B ubiquitin-conjugating enzymes target repressors of cyclic AMP-induced transcription for proteolysis. Mol Cell Biol 19: 5001-5013, 1999.
7. Forgacs E, Gupta SK, Kerry JA and Semmes JO: The bZIP transcription factor ATFx binds human T-cell leukemia virus type 1 (HTLV-1) tax and represses HTLV-1 long terminal repeat-mediated transcription. J Virol 79: 6932-6939, 2005.
8. White JH, McIllhinney RA, Wise A, Ciruela F, Chan WY, Emson PC, Billinton A and Marshall FH: The GABAB receptor interacts directly with the related transcription factors CREB2 and ATFx. Proc Natl Acad Sci USA 97: 13967-13972, 2000.
9. Liu WJ, Sun MY, Jiang JH, et al: Cyclin D3 interacts with human activating transcription factor 5 and potentiates its transcription activity. Biochem Biophys Res Commun 321: 954-960, 2004.
10. Peters CS, Liang XP, Li SX, Kannan S, Peng Y, Taub R and Diamond RH: ATF-7, a novel bZIP protein, interacts with the PRL-1 protein-tyrosine phosphatase. J Biol Chem 276: 13718-13726, 2001.
11. Morris JA, Kandpal G, Ma L and Austin CP: DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum Mol Genet 12: 1591-1608, 2003.
12. Hai TW, Liu F, Coukos WJ and Green MR: Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev 3: 2083-2090, 1989.
13. Mora J, Cheung NKV, Chen LS, Qin J and Gerald W: Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res 7: 1358-1361, 2001.
14. Angelastro JM, Ignatova TN, Kukekov VG, Steindler DA, Stengren GB, Mendelsohn C and Greene LA: Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. J Neurosci 23: 4590-4600, 2003.
15. Chow LSN, Lam CW, Chan SYY, et al: Identification of RASSF1A modulated genes in nasopharyngeal carcinoma. Oncogene 25: 310-316, 2006.
16. Angelastro JM, Canoll PD, Kuo J, Weicker M, Costa A, Bruce JN and Greene LA: Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene 25: 907-916, 2006.
17. Monaco SE, Angelastro JM, Szabolcs M and Greene LA: The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer 120: 1883-1890, 2007.
18. Wang H, Lin G and Zhang Z: ATF5 promotes cell survival through transcriptional activation of Hsp27 in H9c2 cells. Cell Biol Int 31: 1309-1315, 2007.
19. Pascual M, Gomez-Lechon MJ, Castell JV and Jover R: ATF5 is a highly abundant liver-enriched transcription factor that cooperates with constitutive androstane receptor in the transactivation of CYP2B6: implications in hepatic stress responses. Drug Metab Dispos 36: 1063-1072, 2008.
20. Gho JW, Ip WK, Chan KY, Law PT, Lai PB and Wong N: Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest. Cancer Res 68: 6743-6751, 2008.
21. Nishioka T, Miyai Y, Haga H, et al: Novel function of transcription factor ATF5: blockade of p53-dependent apoptosis induced by ionizing irradiation. Cell Struct Funct 34: 17-22, 2009.
22. Li GF, Li WH, Angelastro JM, Greene LA and Liu DX: Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in C6 glioma and MCF-7 breast cancer cells. Mol Cancer Res 7: 933-943, 2009.
23. Greene LA, Lee HY and Angelastro JM: The transcription factor ATF5: role in neurodevelopment and neural tumors. J Neurochem 108: 11-22, 2009.
24. Dong SM, Nutt CL, Betensky RA, et al: Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropath Exp Neur 64: 948-955, 2005.
25. Li YW, Hussain M, Sarkar SH, Eliason J, Li R and Sarkar FH: Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer 5: 7, 2005.
26. Wei YY, Jiang JH, Sun MY, Chen XN, Wang HZ and Gu JX: ATF5 increases cisplatin-induced apoptosis through up-regulation of Cyclin D3 transcription in HeLa cells. Biochem Biophys Res Commun 339: 591-596, 2006.
27. Jass JR, Sobin LH and Watanabe H: The World Health Organization's histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer 66: 2162-2167, 1990.
28. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
29. Bernard PS and Wittwer CT: Real-time PCR technology for cancer diagnostics. Clin Chem 48: 1178-1185, 2002.
30. Wu CC, Shyu RY, Chou JM, Jao SW, et al: RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. Eur J Cancer 42: 557-565, 2006.
31. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
32. Persengiev SP and Green MR: The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis 8: 225-228, 2003.
33. Mason JL, Angelastro JM, Ignatova TN, Kukekov VG, Lin G, Greene LA and Goldman JE: ATF5 regulates the proliferation and differentiation of oligodendrocytes. Mol Cell Neurosci 29: 372-380, 2005.
34. Angelastro JM, Mason JL, Ignatova TN, Kukekov VG, Stengren GB, Goldman JE and Greene LA: Downregulation of activating transcription factor 5 is required for differentiation of neural progenitor cells into astrocytes. J Neurosci 25: 3889-3899, 2005.